Efficacy and safety of larotrectinib in neurotrophic tyrosine receptor kinase fusion-positive solid tumors: A multicenter retrospective cohort study in Korea

被引：0

作者：

Lee, S. ^{[1
]}

Yoon, S. ^{[2
]}

Choi, W. ^{[3
]}

Jung, H. A. ^{[4
]}

Bae, S. B. ^{[5
]}

Kim, C. G. ^{[6
]}

Kim, H. R. ^{[7
]}

Lee, K-w. ^{[8
,14
]}

Kang, E. J. ^{[9
]}

Shin, K. ^{[10
,11
]}

Lim, D-j. ^{[12
]}

Kim, . s.

Park, S. ^{[13
]}

Lee, K-e.

Lee, Y. ^{[15
]}

Kim, H. S. ^{[16
]}

Kim, T. J. ^{[17
]}

Kim, M. J. ^{[18
]}

Kang, J. H. ^{[19
]}

机构：

[1] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Div Med Oncol,Dept Internal Med, Seoul, South Korea

[2] Univ Ulsan, Asan Med Ctr, Oncol Dept, Seoul, South Korea

[3] Ctr Clin Trials, Natl Canc Ctr, NCC, Goyang, South Korea

[4] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr SMC, Div Hematol Oncol,Sch Med, Seoul, South Korea

[5] Soonchunhyang Univ Hosp, Dept Internal Med, Div Hematooncol, Cheonan, South Korea

[6] Yonsei Univ, Div Med Oncol, Dept Internal Med, Yonsei Canc Ctr, Seoul, South Korea

[7] Yonsei Univ, Med Oncol Dept, Yonsei Canc Ctr, Seoul, South Korea

[8] Seoul Natl Univ, Internal Med Dept, Bundang Hosp, Seongnam, South Korea

[9] Korea Univ, Guro Hosp, Dept Internal Med, Div Med Oncol, Seoul, South Korea

[10] Catholic Univ Korea, Internal Med Dept, Seoul, South Korea

[11] Seoul St Marys Hosp, Catholic Med Ctr, Seoul, South Korea

[12] Catholic Univ Korea, Seoul St Marys Hosp, Endocrinol, Seoul, South Korea

[13] Samsung Med Ctr SMC, Hematol & Med Oncol, Seoul, South Korea

[14] Ewha Womans Univ, Mokdong Hosp, Dept Internal Med, Div Hematol Oncol, Seoul, South Korea

[15] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea

[16] Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol, Seoul, South Korea

[17] Catholic Univ Korea, Dept Hosp Pathol, Yeouido St Marys Hosp, Coll Med, Seoul, South Korea

[18] Catholic Univ Korea, Dept Hosp Pathol, Seoul St Marys Hosp, Coll Med, Seoul, South Korea

[19] Catholic Univ Korea, Seoul St Marys Hosp, Catholic Med Ctr, Med Oncol Dept, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.517

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

492P

引用

页数：2

共 50 条

[21] Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
Demetri, George D.
De Braud, Filippo
Drilon, Alexander
Siena, Salvatore
Patel, Manish R.
Cho, Byoung Chul
Liu, Stephen, V
Ahn, Myung-Ju
Chiu, Chao-Hua
Lin, Jessica J.
Goto, Koichi
Lee, Jeeyun
Bazhenova, Lyudmila
John, Thomas
Fakih, Marwan
Chawla, Sant P.
Dziadziuszko, Rafal
Seto, Takashi
Heinzmann, Sebastian
Pitcher, Bethany
Chen, David
Wilson, Timothy R.
Rolfo, Christian
CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1302 - 1312
[22] Off-target resistance to larotrectinib in two patients with NTRK fusion-positive pediatric solid tumors
Lu, S.
Xie, W.
Zhang, Y.
Sun, F.
Huang, J.
Wang, J.
Zhu, J.
Zhen, Z.
Zhang, Y.
ANNALS OF ONCOLOGY, 2023, 34 (11) : 1065 - 1067
[23] Breakthroughs and challenges in the management of tropomyosin receptor kinase fusion-positive tumors
Mamdani, Hirva
Jalal, Shadia I.
ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
[24] Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas
Kummar, Shivaani
Shen, Lin
Hong, David S.
McDermott, Ray
Keedy, Vicki L.
Casanova, Michela
Demetri, George D.
Dowlati, Afshin
Melcon, Soledad Gallego
Lassen, Ulrik N.
Leyvraz, Serge
Liu, Tianshu
Moreno, Victor
Patel, Jyoti
Patil, Tejas
Mallick, Atrayee Basu
Sousa, Nuno
Tahara, Makoto
Ziegler, David S.
Norenberg, Ricarda
Arvis, Pierre
Brega, Nicoletta
Drilon, Alexander
Tan, Daniel S. W.
CANCER, 2023, 129 (23) : 3772 - 3782
[25] Efficacy and Safety of Larotrectinib in Pediatric Patients with Non-Central Nervous System (CNS) Tropomyosin Receptor Kinase (TRK) Fusion-Positive Cancer: An Expanded Dataset
Van Tilburg, C.
Albert, C.
Bielack, S.
Dubois, S.
Federman, N.
Geoerger, B.
Nagasubramanian, R.
Pappo, A.
Norenberg, R.
Dima, L.
De La Cuesta, E.
Zhang, Y.
Doz, F.
Laetsch, T.
PEDIATRIC BLOOD & CANCER, 2021, 68 : S54 - S54
[26] LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN PAEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMOURS
Nysom, Karsten
Doz, Francois
Geoerger, Birgit
Ora, Ingrid
Perreault, Sebastien
Norenberg, Ricarda
Fellous, Marc
De La Cuesta, Esther
Laetsch, Theodore W.
van Tilburg, Cornelis M.
NEURO-ONCOLOGY, 2022, 24 : 64 - 64
[27] Long-term efficacy and safety of larotrectinib in patients with TRK fusion-positive lung cancer.
Lin, Jessica Jiyeong
Kummar, Shivaani
Tan, Daniel Shao-Weng
Lassen, Ulrik Niels
Leyvraz, Serge
Liu, Yongmei
Moreno, Victor
Patel, Jyoti D.
Rosen, Lee S.
Solomon, Benjamin Maurice
Norenberg, Ricarda
Dima, Laura
Brega, Nicoletta
Shen, Lin
Drilon, Alexander E.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[28] Larotrectinib: New Tyrosine Receptor Kinase Inhibitor Approval for NTRK Fusion Tumors independent of Histology
Eiden, Petra
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (11) : 619 - 619
[29] Neurotrophic tyrosine receptor kinase fusion in pediatric central nervous system tumors
Lang, Shih-Shan
Kumar, Nankee K.
Madsen, Peter
Gajjar, Avi A.
Gajjar, Esha
Resnick, Adam C.
Storm, Phillip B.
CANCER GENETICS, 2022, 262 : 64 - 70
[30] Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
Drilon, A.
Moreno, V.
Patel, J.
Lassen, U. N.
Solomon, B.
Rosen, L.
Leyvraz, S.
Tan, D. S. W.
Reeves, J. A.
Dima, L.
Brega, N.
Kummar, S.
Farago, A. F.
ANNALS OF ONCOLOGY, 2020, 31 : S834 - S834

← 1 2 3 4 5 →